Drugmakers tap China AI app boom to reach doctors as crackdown upends marketing
Executive Brief • Key Highlights
Fast factual intelligence distilled for busy investors, executives, and answer bots:
- ✓Drugmakers in China are using AI apps to reach doctors after a graft crackdown hurt traditional marketing.
- ✓Alibaba Health and other firms now offer digital platforms for companies to share clinical research.
- ✓Wang Xiangzhi said, "Today, many pharmaceutical companies, in order to influence doctors, need to invest large marketing budgets."
Story at a Glance
- Category
- Indian Markets
- Reported By
- Reuters
- Reading Speed
- 3 Minute(s)
- Market Focus
- India Economy
SHANGHAI, Nov 11 (Reuters) - Drugmakers in China are seizing on a boom in digital assistants that has opened up a new — and potentially more efficient — way to connect with doctors after a sweeping graft crackdown disrupted traditional engagement channels.
Sign up here.
Drugmakers are racing to leverage the technology, exploring potential marketing opportunities with app makers or customising platforms around specific diseases for use by physicians, tech executives said, after Beijing's increased scrutiny of hospital visits made doctor outreach more difficult and hurt sales.
The added impetus to shift marketing budgets to digital channels could be a boon for the health-tech companies making the apps, offering a new revenue stream in a market facing rising competition and weak Chinese consumption.
Unlock the Full Story with ArthNow Premium
To continue reading this complete financial story and in-depth market context, upgrade to ArthNow Premium. Enjoy unlimited access across Web and Mobile.
Reuters
Read the full, original unfiltered story directly on the publisher's portal.
This brief is for information only and is not investment advice. ArthNow is not a SEBI-registered investment adviser and does not publish buy or sell recommendations. Original reporting is credited to the publisher named above. Read our editorial policy or report an error.